September 14, 2020
1 min read

Enspryng reduces risk, severity of relapse in neuromyelitis optica spectrum disorder

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Enspryng lowered relapse severity in patients with neuromyelitis optica spectrum disorder, according to data from the double-masked periods of the SAkura phase 3 studies presented at the MSVirtual2020 meeting.

According to a Genentech press release, a post hoc analysis found the risk for severe relapse was reduced by 79% in the group treated with Enspryng (satralizumab-mwge, Genentech) compared with the group treated with placebo.

In a separate pooled analysis of the combined double-masked period and open-label extension, satralizumab reduced relapse risk by 51% compared with those originally in the placebo group.

Additionally, in the double-masked periods, infection rates were lower in the satralizumab-treated group compared with the placebo-treated group in the SAkuraStar study. Infection rates did not differ between groups in the SAkuraSky study.

In August, the FDA approved Enspryng for adults with anti-aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.